|1.||Gmiro, V E: 5 articles (07/2008 - 05/2000)|
|2.||Serdyuk, S E: 3 articles (07/2008 - 05/2007)|
|3.||Crossman, Alan R: 2 articles (09/2013 - 07/2010)|
|4.||Ravenscroft, Paula: 2 articles (09/2013 - 07/2010)|
|5.||Kobylecki, Christopher: 2 articles (09/2013 - 07/2010)|
|6.||Serdiuk, S E: 2 articles (07/2008 - 05/2000)|
|7.||Efremov, O M: 2 articles (07/2008 - 05/2007)|
|8.||Leventhal, Daniel K: 1 article (11/2011)|
|9.||Berke, Joshua D: 1 article (11/2011)|
|10.||Pettibone, Jeffrey R: 1 article (11/2011)|
07/01/2008 - "Intracerebral and peripheral (intraperitoneal) administration of compound IEM-1460 with the Me3N+ group was equally potent in reducing the severity of nicotine-induced seizures in mice. "
07/01/2008 - "Peripheral and central routes of administration of quaternary ammonium compound IEM-1460 are equally potent in reducing the severity of nicotine-induced seizures in mice."
05/01/2007 - "Systemic intraperitoneal administration of polyamine agonist IEM-1460 containing the Me3N(+) group with a stable positive charge preventing permeation of this substance through the blood-brain barrier and polyamine antagonist arcaine had no effect on the development of seizures caused by intracerebral injection of N-methyl-D-aspartate in mice. "
05/01/2007 - "IEM-1460 blocking both GluR1 AMPA receptors and alpha3beta4 nicotinic acetylcholine receptors, injected intramuscularly in doses of 0.5-3.0 mg/kg produced the maximum anticonvulsant activity and 8-fold decreased the incidence of kainate-induced tonic-clonic seizures and mortality rate."
07/01/2008 - "Bis-ammonium compound IEM-1460 (containing adamantyl radical), which blocks both GluR1 AMPA receptors and alpha3beta4 N-cholinoreceptors, in a range of doses 0.1 - 3 mg/kg produces a 5- to 8-fold decrease in the frequency and virtually completely eliminates lethality of both clonic-tonic nicotinic and kainate seizures. "
09/01/2013 - "Antagonists at glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, such as IEM 1460, reduce induction and expression of dyskinesia in rat and non-human primate models of PD. "
07/01/2010 - "The acute effects of the Ca(2+)-permeable AMPA receptor antagonist 1-trimethylammonio-5-(1-adamantane-methylammoniopentane) dibromide hydrobromide (IEM 1460) on abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat and LID in the MPTP-lesioned non-human primate were assessed. "
|3.||Dystonia (Limb Dystonia)
|1.||AMPA Receptors (AMPA Receptor)
|2.||Kainic Acid (Kainate)
|3.||Quaternary Ammonium Compounds (Ammonium)
|5.||Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
|7.||Glutamate Receptors (Glutamate Receptor)
|8.||Oxidopamine (6 Hydroxydopamine)
|9.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)